2018
DOI: 10.1002/ijc.31983
|View full text |Cite
|
Sign up to set email alerts
|

Glioblastoma endothelium drives bevacizumab‐induced infiltrative growth via modulation of PLXDC1

Abstract: Bevacizumab, a VEGF‐targeting monoclonal antibody, may trigger an infiltrative growth pattern in glioblastoma. We investigated this pattern using both a human specimen and rat models. In the human specimen, a substantial fraction of infiltrating tumor cells were located along perivascular spaces in close relationship with endothelial cells. Brain xenografts of U87MG cells treated with bevacizumab were smaller than controls (p = 0.0055; Student t‐test), however, bands of tumor cells spread through the brain far… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
43
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 27 publications
(44 citation statements)
references
References 56 publications
(80 reference statements)
1
43
0
Order By: Relevance
“…Here, we used the antibody targeting Collapsin Response Mediator Protein 5 (CRMP5) that was recently proposed as a selective tumor marker for glioma cells [24,25]. Previously, we validated this antibody on patient-derived GSCs with mutant IDH1 [26]. Here, we used surgical specimens of low-grade glioma (WHO grade II astrocytoma and oligodendroglioma) with mutant IDH1/2 and showed a co-staining of the tumor cells with anti-IDH1 and anti-CRMP5 antibodies (Supplementary Figure S5 and Supplementary Table S2).…”
Section: Perivascular Invasion and Disruption Of Bbb In Human Specimementioning
confidence: 99%
See 1 more Smart Citation
“…Here, we used the antibody targeting Collapsin Response Mediator Protein 5 (CRMP5) that was recently proposed as a selective tumor marker for glioma cells [24,25]. Previously, we validated this antibody on patient-derived GSCs with mutant IDH1 [26]. Here, we used surgical specimens of low-grade glioma (WHO grade II astrocytoma and oligodendroglioma) with mutant IDH1/2 and showed a co-staining of the tumor cells with anti-IDH1 and anti-CRMP5 antibodies (Supplementary Figure S5 and Supplementary Table S2).…”
Section: Perivascular Invasion and Disruption Of Bbb In Human Specimementioning
confidence: 99%
“…Immunosuppressed athymic rats (male, 250-280 g; Charles River, Milan, Italy) were used for brain xenografts [26] (Supplementary materials and methods).…”
Section: Intracranial Xenografts Of Gfp Expressing U87mg Gsc1 and Gmentioning
confidence: 99%
“…In glioblastoma, Bevacizumab may trigger a phenotypic change of the tumor that undergoes a gliomatosis-like growth pattern. This infiltrative shift occurs mostly along perivascular spaces and relies on the over-expression of PLXDC1 (Plexin Domain Containing 1) by tumor cells and on the restoration of the endothelial component of blood brain barrier [ 78 ]. When targeting tumor angiogenesis, we should consider that a functional tumor vasculature allows the access in the tumor mass of therapeutic drugs and cells of the immune system.…”
Section: Therapy-induced Senescence Of Tumor Vasculaturementioning
confidence: 99%
“…Finally, the fact that a mutant that was deleted in both the Eph and the Plxdc1/2 interaction motif, RRV-YFP gH∆21-27-AELAAN, was still able to replicate on rhesus monkey fibroblasts, as evidenced by the fact that we were able to grow a virus stock on these cells, and was still infectious to a certain degree on a number of cell lines ( Similarly, Plxdc1 was first described in a screen for novel tumor endothelial members (25) and expression of both Plxdc1 and Plxdc2 is elevated in the endothelium of solid tumors (25,26,42,43). Plxdc1 expression has been described as prognostic marker and modulating factor for various human cancers (42)(43)(44)(45)(46). Given the overlap between the required changes e.g.…”
Section: Ebv and Hcmv A Clear Correlation Between Receptor Usage Dementioning
confidence: 99%